Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Identifieur interne : 000512 ( Ncbi/Checkpoint ); précédent : 000511; suivant : 000513Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Auteurs : P. Del Dotto [Italie] ; N. Pavese ; G. Gambaccini ; S. Bernardini ; L V Metman ; T N Chase ; U. BonuccelliSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2001.
English descriptors
- KwdEn :
- Aged, Amantadine (administration & dosage), Amantadine (therapeutic use), Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Dopamine Agents (administration & dosage), Dopamine Agents (therapeutic use), Double-Blind Method, Drug Therapy, Combination, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Female, Humans, Infusions, Intravenous, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors), Receptors, N-Methyl-D-Aspartate (metabolism), Remission Induction.
- MESH :
- chemical , administration & dosage : Amantadine, Antiparkinson Agents, Dopamine Agents.
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , antagonists & inhibitors : Receptors, N-Methyl-D-Aspartate.
- chemical , metabolism : Receptors, N-Methyl-D-Aspartate.
- chemical , therapeutic use : Amantadine, Antiparkinson Agents, Dopamine Agents, Levodopa.
- complications : Parkinson Disease.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- Aged, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Remission Induction.
Abstract
Experimental evidence suggests that glutamatergic receptor blockade may improve the motor response complications associated with long-term levodopa treatment in Parkinson's disease (PD) patients. Our objective was to evaluate the acute effect of amantadine, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, on levodopa-induced dyskinesias, and to gain further insights into the antidyskinetic mechanism of this drug. Nine PD patients with motor fluctuations and severely disabling peak of dose dyskinesias received their first morning levodopa dose, followed by a 2-hour intravenous amantadine (200 mg) or placebo infusion, on two different days. Parkinsonian symptoms and dyskinesias were assessed every 15 minutes during the infusion and for 3 hours thereafter, while patients were taking their usual oral antiparkinsonian therapy, by means of Unified Parkinson's Disease Rating Scale (UPDRS, motor examination), tapping test, and a modified Abnormal Involuntary Movement Scale (AIMS). Intravenous amantadine acutely improved levodopa-induced dyskinesias by 50%without any loss of the anti-parkinsonian benefit from levodopa. This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations.
PubMed: 11391748
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003D39
- to stream PubMed, to step Curation: 003D39
- to stream PubMed, to step Checkpoint: 003D18
- to stream Ncbi, to step Merge: 000512
- to stream Ncbi, to step Curation: 000512
Links to Exploration step
pubmed:11391748Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.</title><author><name sortKey="Del Dotto, P" sort="Del Dotto, P" uniqKey="Del Dotto P" first="P" last="Del Dotto">P. Del Dotto</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neuroscience, Neurology Section, University of Pisa, Via Roma 67, 56100 Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neuroscience, Neurology Section, University of Pisa, Via Roma 67, 56100 Pisa</wicri:regionArea><wicri:noRegion>56100 Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Pavese, N" sort="Pavese, N" uniqKey="Pavese N" first="N" last="Pavese">N. Pavese</name></author><author><name sortKey="Gambaccini, G" sort="Gambaccini, G" uniqKey="Gambaccini G" first="G" last="Gambaccini">G. Gambaccini</name></author><author><name sortKey="Bernardini, S" sort="Bernardini, S" uniqKey="Bernardini S" first="S" last="Bernardini">S. Bernardini</name></author><author><name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L V" last="Metman">L V Metman</name></author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T N" last="Chase">T N Chase</name></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U" last="Bonuccelli">U. Bonuccelli</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11391748</idno><idno type="pmid">11391748</idno><idno type="wicri:Area/PubMed/Corpus">003D39</idno><idno type="wicri:Area/PubMed/Curation">003D39</idno><idno type="wicri:Area/PubMed/Checkpoint">003D18</idno><idno type="wicri:Area/Ncbi/Merge">000512</idno><idno type="wicri:Area/Ncbi/Curation">000512</idno><idno type="wicri:Area/Ncbi/Checkpoint">000512</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.</title><author><name sortKey="Del Dotto, P" sort="Del Dotto, P" uniqKey="Del Dotto P" first="P" last="Del Dotto">P. Del Dotto</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neuroscience, Neurology Section, University of Pisa, Via Roma 67, 56100 Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neuroscience, Neurology Section, University of Pisa, Via Roma 67, 56100 Pisa</wicri:regionArea><wicri:noRegion>56100 Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Pavese, N" sort="Pavese, N" uniqKey="Pavese N" first="N" last="Pavese">N. Pavese</name></author><author><name sortKey="Gambaccini, G" sort="Gambaccini, G" uniqKey="Gambaccini G" first="G" last="Gambaccini">G. Gambaccini</name></author><author><name sortKey="Bernardini, S" sort="Bernardini, S" uniqKey="Bernardini S" first="S" last="Bernardini">S. Bernardini</name></author><author><name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L V" last="Metman">L V Metman</name></author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T N" last="Chase">T N Chase</name></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U" last="Bonuccelli">U. Bonuccelli</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Amantadine (administration & dosage)</term><term>Amantadine (therapeutic use)</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dopamine Agents (administration & dosage)</term><term>Dopamine Agents (therapeutic use)</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Female</term><term>Humans</term><term>Infusions, Intravenous</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)</term><term>Receptors, N-Methyl-D-Aspartate (metabolism)</term><term>Remission Induction</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term><term>Dopamine Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Infusions, Intravenous</term><term>Male</term><term>Middle Aged</term><term>Remission Induction</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Experimental evidence suggests that glutamatergic receptor blockade may improve the motor response complications associated with long-term levodopa treatment in Parkinson's disease (PD) patients. Our objective was to evaluate the acute effect of amantadine, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, on levodopa-induced dyskinesias, and to gain further insights into the antidyskinetic mechanism of this drug. Nine PD patients with motor fluctuations and severely disabling peak of dose dyskinesias received their first morning levodopa dose, followed by a 2-hour intravenous amantadine (200 mg) or placebo infusion, on two different days. Parkinsonian symptoms and dyskinesias were assessed every 15 minutes during the infusion and for 3 hours thereafter, while patients were taking their usual oral antiparkinsonian therapy, by means of Unified Parkinson's Disease Rating Scale (UPDRS, motor examination), tapping test, and a modified Abnormal Involuntary Movement Scale (AIMS). Intravenous amantadine acutely improved levodopa-induced dyskinesias by 50%without any loss of the anti-parkinsonian benefit from levodopa. This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations.</div></front></TEI><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Bernardini, S" sort="Bernardini, S" uniqKey="Bernardini S" first="S" last="Bernardini">S. Bernardini</name><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U" last="Bonuccelli">U. Bonuccelli</name><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T N" last="Chase">T N Chase</name><name sortKey="Gambaccini, G" sort="Gambaccini, G" uniqKey="Gambaccini G" first="G" last="Gambaccini">G. Gambaccini</name><name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L V" last="Metman">L V Metman</name><name sortKey="Pavese, N" sort="Pavese, N" uniqKey="Pavese N" first="N" last="Pavese">N. Pavese</name></noCountry><country name="Italie"><noRegion><name sortKey="Del Dotto, P" sort="Del Dotto, P" uniqKey="Del Dotto P" first="P" last="Del Dotto">P. Del Dotto</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000512 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000512 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:11391748
|texte= Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:11391748" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |